DUALSAVE-FGS is a partnership of nine African and European institutions developing a cost-effective joint screening method for Female Genital Schistosomiasis and cervical cancer.

The partners will clinically validate the Spectral Artificial Vision (SAVE) colposcope, invented and developed by our partner QCELL, a biophotonics imaging company based in Greece.

SAVE is a low-cost, hand-held digital colposcope, integrating the most advanced spectral imaging and machine learning technologies with the possibility for large-scale implementation.

SAVE is capable of identifying cervical (pre-)cancer and hopefully FGS, instantly, and without being in contact with the patient. DUALSAVE-FGS will also provide virtual training of frontline primary health care professionals and gynaecologists in FGS diagnosis and management. A social science study will be carried out, to learn how procedures are perceived by patients and health professional.

Project Areas: South Africa | Eswatini | Mozambique